诊断和治疗 艰难的 Clostridioides 感染的诊断和治疗
1Division of Infection Control and Prevention, Nippon Medical School Chiba Hokusoh Hospital.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
|March 11, 2026
概括
艰难杆菌感染 (CDI) 的管理需要准确的诊断和量身定制的治疗. 本综述比较了国际和日本对CDI诊断,严重程度,复发预测和治疗的方法,强调了改善患者结果的特定区域策略.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 艰难菌感染 (CDI) 是全球与医疗保健相关的腹的主要原因.
- 与CDI相关的高发病率,复发率和医疗费用需要改进的管理策略.
研究的目的:
- 为CDI管理提供全面的概述,重点关注诊断标准,严重程度分类,复发预测和治疗选择.
- 为了比较国际和日本对CDI护理的观点,强调特定区域的考虑.
主要方法:
- 对诊断标准的审查,包括布里斯托尔便尺度和便检测协议.
- 对严重程度分类系统的分析 (例如,MN标准与国际准则).
- 评估复发预测模型 (CHIEF评分,DASC指标) 和治疗剂 (fidaxomicin,vancomycin,metronidazole) 的使用情况.
主要成果:
- 日本使用了MN严重性标准,整合了临床,实验室和成像发现,这可能更适合当地实践,而不是基于国际实验室的分类.
- 在日本队伍中开发的CHIEF评分和DASC指标有助于识别患有CDI复发高风险的患者.
- 由于其对微生物群的节约作用,菲达克索米辛在国际上受到青,而由于菌株的流行和成本,在日本,甲尼达仍然是轻度CDI的成本有效选择.
结论:
- 优化CDI管理需要整合特定区域的数据,并考虑当地实践.
- 进一步整合风险分层工具和新兴治疗策略对于改善多种环境中的CDI护理至关重要.
- 准确的诊断和量身定制的治疗方法对于减少CDI发病率和医疗负担至关重要.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
994
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
994
Drugs for Treatment of Diarrhea-Predominant IBS
829
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
829
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
Inflammatory Bowel Disease IV: Pharmacological Management
884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
884


